

# AGE-RELATED MACULAR DEGENERATION (ARMD)

- ARMD
- 15 million affected in the US
- 25-30 million affected worldwide
- Affects 30% of people 64-75 years old
  
- Two Forms
- Wet ARMD
  - Only 10% of cases progress to Wet form
- Dry ARMD
  - 90% of cases
  - No FDA approved therapies
  - No cures



Central vision deteriorates leading to total blindness

# DRY ARMD PILOT TRIAL

- **Single-center trial**
  - 20 Dry ARMD patients over the age of 50
  - Patients receive treatment for two twenty minute sessions per day
- **Endpoints:**
  - Safety
  - Efficacy – measured across four endpoints
    - Near and Distance BCVA (Best Corrected Visual Acuity)
    - Contrast Sensitivity
    - Anatomical change
- 20 patients completed 6 months as of September 2008

# DRY ARMD – Clinical Results

## (6-18 Months of Data)

### Results\*

- Safety
  - No device-related safety events
- Efficacy
  - BCVA improved for all 3 stages of patients
  - Contrast Sensitivity improved for all 3 stages of patients
  - Anatomical analysis showed a lack of disease progression in some patients

	Stage		
	Early	Middle	Late
Visual Acuity	+	+	+
Contrast Sensitivity	+	+	+
Disease Progression	+	+	+

logMAR Chart



\*As presented at:

- ISCEV (International Society of Clinicians in the Electrophysiology of Vision), Morgantown, WV, July 2008, general session presentation
- Retina Society, Scottsdale, AZ, Sept. 2008, general session presentation
- AAO (American Academy of Ophthalmology), Atlanta, November 2008, poster presentation